Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anagenics ( (AU:AN1) ) has shared an announcement.
Anagenics Limited has disclosed that FOS Capital Ltd has ceased to be a substantial shareholder in the company, effective 9 February 2026. The change follows a dilution of FOS Capital’s voting power arising from an increase in Anagenics’ total shares on issue, rather than from a direct sale of its holdings.
The notice signals a shift in Anagenics’ share register composition, which may incrementally broaden the shareholder base and alter voting dynamics. While no transaction consideration was involved, the move underscores how capital management or new share issuance can reshape substantial holdings and influence governance influence over time.
More about Anagenics
Anagenics Limited operates in the healthcare and biotechnology sector, with a focus on life sciences and wellness-related products. The company is listed on the Australian Securities Exchange and attracts investment from institutional and professional shareholders active in small-cap and specialty health stocks.
Current Market Cap: A$3.42M
See more data about AN1 stock on TipRanks’ Stock Analysis page.